Abstract
TNF-receptor associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene. The IL-1 receptor antagonist anakinra has been reported to be an efficacious daily treatment. Canakinumab (CAN) is a fully human monoclonal selective anti-IL-1β antibody with a T1/2 of ~4 wks. Interim clinical and PK data of CAN treatment in patients with active TRAPS are presented.
Highlights
TNF-receptor associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene
Primary endpoint was complete or almost complete response at Day 15 based on physician assessed absent or minimal TRAPS signs/symptoms and normal or ≥70% reduced CRP and/or SAA
Population PK analysis was performed using NONMEM based on CAN concentrations determined by ELISA from blood samples collected at prespecified times points during the first month, at each pre-dose of CAN, and at flares thereafter
Summary
TNF-receptor associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene. The IL-1 receptor antagonist anakinra has been reported to be an efficacious daily treatment. Canakinumab (CAN) is a fully human monoclonal selective anti-IL-1b antibody with a T1/2 of ~4 wks. Interim clinical and PK data of CAN treatment in patients with active TRAPS are presented
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
